Active ingredientLusutrombopagCat. No. P-L113-001CAS 1110766-97-6Family · Pharmaceutical analytical standards
Lusutrombopag
A thrombopoietin receptor agonist that stimulates platelet production; approved in Japan in 2015, in the United States in 2018 and in Europe in 2019 for low platelets in patients with chronic liver disease before a planned invasive procedure. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?The suffix '-trombopag' is shared by thrombopoietin receptor agonists such as eltrombopag and avatrombopag: it marks molecules that mimic the hormone regulating platelet production.
Go to the active ingredient →Active ingredientLusutrombopagCat. No. P-L113-001CAS 1110766-97-6
Isotopically labelledLusutrombopag-d13Cat. No. P-L113-002
ImpurityLusutrombopag Impurity 1Cat. No. P-L113-003CAS 1110767-89-9
Impurity4,6-Dichloro-2-benzofuran-1(3H)-oneCat. No. P-L113-004CAS 52043-45-5
Impurityent-LusutrombopagCat. No. P-L113-005CAS 1110767-77-5
ImpurityLusutrombopag Ethyl esterCat. No. P-L113-006
ImpurityLusutrombopag Impurity 2Cat. No. P-L113-007
ImpurityLusutrombopag Impurity 3Cat. No. P-L113-008No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.